Health Catalyst, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 14, 2022, details the results of Health Catalyst, Inc.'s annual meeting of stockholders. The filing covers the voting outcomes for three specific proposals presented to shareholders.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
The following material events occurred at the Annual Meeting:
- Shareholder Participation: Of 53,937,142 shares entitled to vote, 46,176,662 shares were present or represented by proxy.
- Proposal 1 (Election of Directors): Stockholders elected Duncan Gallagher and Mark B. Templeton as Class III directors for a three-year term. Both candidates received majority support, though a significant number of votes were withheld for Mr. Gallagher (14,766,137 withheld vs. 28,400,049 for).
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 45,758,062 votes in favor.
- Proposal 3 (Executive Compensation): Stockholders did not approve the non-binding, advisory proposal to approve the compensation of the Company's named executive officers. The vote resulted in 23,100,748 votes against versus 20,019,370 votes for.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or outlook. The rejection of the executive compensation proposal (Proposal 3) represents a significant governance event that may indicate shareholder dissatisfaction with current pay structures, though the filing does not elaborate on the specific reasons for the rejection.
Investor Verification Checklist
- Verify the Company's response to the rejection of the executive compensation advisory vote (Proposal 3).
- Review the definitive proxy statement filed on April 27, 2022, for detailed context on the director nominees and executive compensation packages.
- Monitor future filings for any changes to executive compensation policies or board composition resulting from the voting outcomes.